Related Experiment Video

Updated: Apr 3, 2026

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation
15:05

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation

Published on: May 20, 2020

9.5K

Identifying activating mutations in the EGFR gene: prognostic and therapeutic implications in non-small cell lung

Gabriel Lima Lopes1, Edoardo Filippo de Queiroz Vattimo2, Gilberto de Castro Junior2

  • 1Hospital Sírio-Libanês, São Paulo, SP, BR.

Jornal Brasileiro De Pneumologia : Publicacao Oficial Da Sociedade Brasileira De Pneumologia E Tisilogia
|September 24, 2015
PubMed

Insights

Identifying EGFR mutations in non-small cell lung cancer (NSCLC) is crucial. Targeted therapies like EGFR tyrosine-kinase inhibitors (EGFR-TKIs) significantly improve outcomes for patients with these specific mutations.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Lung cancer remains a leading cause of cancer mortality globally.
  • Signal transduction pathways, particularly the Epidermal Growth Factor Receptor (EGFR) pathway, are key targets for novel cancer therapies.
  • Activating mutations in the EGFR gene are present in about 10% of non-squamous non-small cell lung cancer (NSCLC) patients.

Purpose of the Study:

  • To review EGFR pathway activation in NSCLC.
  • To emphasize the importance of identifying EGFR gene mutations.
  • To discuss the outcomes of EGFR tyrosine-kinase inhibitor (EGFR-TKI) treatment in NSCLC.

Main Methods:

  • Review of clinical trials and studies on EGFR-TKIs (gefitinib, erlotinib, afatinib).
  • Comparison of EGFR-TKIs with platinum-based regimens in first-line treatment for chemotherapy-naïve patients.
  • Analysis of EGFR-TKI efficacy in advanced NSCLC as second- and third-line therapies.

Main Results:

  • EGFR-TKIs demonstrate improved progression-free survival and overall response rates compared to chemotherapy in patients with activating EGFR mutations.
  • EGFR-TKIs are effective in both first-line and later-line treatment settings for advanced NSCLC.
  • The presence of specific EGFR gene mutations (exon 19 deletions, L858R mutation) predicts response to EGFR-TKIs.

Conclusions:

  • Accurate identification of activating EGFR mutations is essential for effective NSCLC treatment.
  • EGFR-TKIs represent a significant advancement in personalized medicine for NSCLC patients with specific genetic profiles.
  • Targeting the EGFR pathway offers a promising therapeutic strategy for improving survival in NSCLC.

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

9.3K
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.8K

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
12.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
7.5K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
68